{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T23:08:09Z","timestamp":1773184089506,"version":"3.50.1"},"reference-count":33,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Russian academic excellence project \u201c5-100&quot; for Sechenov First Moscow State Medical University","award":["1\/15"],"award-info":[{"award-number":["1\/15"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Background: bladder cancer is one of the most common urinary tract malignancies. Establishment of robust predictors of disease progression and outcome is important for personalizing treatment of non-muscular invasive bladder carcinoma (NMIBC). In this study we evaluated association of PD-L1 expression with other prognostic biomarkers, such as expression of miRNA-145 and miRNA-200a, FGFR3 gene expression, and mutation status in tissue specimens of the luminal subtype of newly diagnosed high and low grade NMIBC. Methods: twenty patients with primary luminal NMIBC were enrolled in the study. Tumor grade and risk level were determined in accordance with European Organization for Research and Treatment of Cancer (EORTC) guidelines and World Health Organization (WHO) classification. Neoplasm molecular subtype and PD-L1 expression level were assessed by immunohistochemistry. We used real-time PCR to evaluate the expression of microRNAs and FGFR3. We detected FGFR3 hotspot mutations in codons 248 and 249 by Sanger sequencing. Results: high grade primary luminal NMIBC showed comparatively higher expression of PD-L1 and microRNA-145 than a low grade tumor, whereas the latter had a higher FGFR3 expression and hotspot mutation rate. The tumor grade (HR = 571.72 [11.03\u20132.96] p = 0.002), PD-L1 expression (HR = 2.33 [0.92\u20131.92] p = 0.012), and FGFR3 expression (HR = 0.08 [0.17\u20130.42] p = 0.003) were associated with relapse-free survival. Conclusions: tumor grade in association with PD-L1 and FGFR3 expression can be considered as a complex predictor for primary luminal NMIBC progression.<\/jats:p>","DOI":"10.3390\/life10110305","type":"journal-article","created":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T11:50:34Z","timestamp":1606132234000},"page":"305","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Prognostic Role of FGFR3 Expression Status and Tumor-Related MicroRNAs Level in Association with PD-L1 Expression in Primary Luminal Non-Muscular Invasive Bladder Carcinoma"],"prefix":"10.3390","volume":"10","author":[{"given":"Ekaterina","family":"Blinova","sequence":"first","affiliation":[{"name":"Department of Clinical Anatomy and Operative Surgery, Department of Pathological Anatomy, Institute for Urology and Reproductive Health, Sechenov University, 119991 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton","family":"Buzdin","sequence":"additional","affiliation":[{"name":"Laboratory of Bioinformatics, Institute for Personalized Medicine, Sechenov University, 119991 Moscow, Russia"},{"name":"Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitry","family":"Enikeev","sequence":"additional","affiliation":[{"name":"Department of Clinical Anatomy and Operative Surgery, Department of Pathological Anatomy, Institute for Urology and Reproductive Health, Sechenov University, 119991 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitry","family":"Roshchin","sequence":"additional","affiliation":[{"name":"Russian National Research Center of Radiology, Department of Oncological Urology, 125284 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Suntsova","sequence":"additional","affiliation":[{"name":"Laboratory of Bioinformatics, Institute for Personalized Medicine, Sechenov University, 119991 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Samyshina","sequence":"additional","affiliation":[{"name":"All-Union Research Center for Biological Active Compounds Safety, Laboratory of Molecular Pharmacology and Drug Design, 142450 Staraja Kupavna, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksey","family":"Drobyshev","sequence":"additional","affiliation":[{"name":"Laboratory of Bioinformatics, Institute for Personalized Medicine, Sechenov University, 119991 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Deryabina","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology, Department of Oncology, National Research Ogarev Mordovia State University, 430005 Saransk, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana","family":"Demura","sequence":"additional","affiliation":[{"name":"Department of Clinical Anatomy and Operative Surgery, Department of Pathological Anatomy, Institute for Urology and Reproductive Health, Sechenov University, 119991 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8385-4356","authenticated-orcid":false,"given":"Dmitry","family":"Blinov","sequence":"additional","affiliation":[{"name":"All-Union Research Center for Biological Active Compounds Safety, Laboratory of Molecular Pharmacology and Drug Design, 142450 Staraja Kupavna, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evgenia","family":"Shich","sequence":"additional","affiliation":[{"name":"Department of Clinical Anatomy and Operative Surgery, Department of Pathological Anatomy, Institute for Urology and Reproductive Health, Sechenov University, 119991 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0911-3063","authenticated-orcid":false,"given":"Haydar","family":"Barakat","sequence":"additional","affiliation":[{"name":"Department of Propaedeutics of Dental Diseases, People\u2019s Friendship University of Russia, 117198 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter","family":"Borger","sequence":"additional","affiliation":[{"name":"Laboratory of the Swiss Hepato-Pancreato-Biliary and Transplantation Center, Department of Surgery, University Hospital Z\u00fcrich, 8091 Z\u00fcrich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitrij","family":"Merinov","sequence":"additional","affiliation":[{"name":"Russian National Research Center of Radiology, Department of Oncological Urology, 125284 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandr","family":"Kachmazov","sequence":"additional","affiliation":[{"name":"Russian National Research Center of Radiology, Department of Oncological Urology, 125284 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanislav","family":"Serebrianyi","sequence":"additional","affiliation":[{"name":"Russian National Research Center of Radiology, Department of Oncological Urology, 125284 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oxana","family":"Tumutolova","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology, Department of Oncology, National Research Ogarev Mordovia State University, 430005 Saransk, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Potoldykova","sequence":"additional","affiliation":[{"name":"Department of Clinical Anatomy and Operative Surgery, Department of Pathological Anatomy, Institute for Urology and Reproductive Health, Sechenov University, 119991 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Zhdanov","sequence":"additional","affiliation":[{"name":"Department of Clinical Anatomy and Operative Surgery, Department of Pathological Anatomy, Institute for Urology and Reproductive Health, Sechenov University, 119991 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vagarshak","family":"Grigoryan","sequence":"additional","affiliation":[{"name":"Department of Clinical Anatomy and Operative Surgery, Department of Pathological Anatomy, Institute for Urology and Reproductive Health, Sechenov University, 119991 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitrij","family":"Perepechin","sequence":"additional","affiliation":[{"name":"Russian National Research Center of Radiology, Department of Oncological Urology, 125284 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,11,23]]},"reference":[{"key":"ref_1","first-page":"18","article-title":"Bladder Cancer in Males: A Comprehensive Review of Urothelial Carcinoma of the Bladder","volume":"11","author":"Murphy","year":"2014","journal-title":"J. Men\u2019s Health"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/BF03262330","article-title":"The health economics of bladder cancer: A comprehensive review of published literature","volume":"21","author":"Botteman","year":"2003","journal-title":"PharmacoEconomics"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","article-title":"Bladder cancer","volume":"388","author":"Kamat","year":"2016","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrclinonc.2017.195","article-title":"Bladder cancer: Multi-omic profiling refines the molecular view","volume":"15","author":"Hurst","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/CCO.0000000000000173","article-title":"Management of noninvasive bladder cancers","volume":"27","author":"Eifler","year":"2015","journal-title":"Curr. Opin. Oncol."},{"key":"ref_6","first-page":"105","article-title":"Meta-analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use","volume":"12","author":"Dadhania","year":"2016","journal-title":"Oncotarget"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00262-006-0272-1","article-title":"Contribution of the PD-L1\/PD-1 pathway to T-cell exhaustion: An update on implications for chronic infections and tumor evasion","volume":"56","author":"Blank","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.2016.67.9761","article-title":"Safety and Efficacy of Durvalumab (MEDI4736), an Anti\u2013Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients with Advanced Urothelial Bladder Cancer","volume":"34","author":"Massard","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12894-018-0414-8","article-title":"PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer","volume":"18","author":"Kawahara","year":"2018","journal-title":"BMC Urol."},{"key":"ref_11","first-page":"S104","article-title":"Heterogeneity in PD-L1 expression and CD8+ infiltrates in low grade versus high grade serous ovarian carcinomas","volume":"Volume 469","author":"Louvet","year":"2016","journal-title":"Virchows Archiv"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Blinova, E., Enikeev, D., Roshchin, D., Samyshina, E., Deryabina, O., Swidsinski, A., Blinov, D., Kogan, E.A., Dudina, M., and Barakat, H. (2020). Relapse-Free Survival and PD-L1 Expression in First High- and Low-Grade Relapsed Luminal, Basal and Double-Negative P53-Mutant Non-Muscular Invasive Bladder Cancer Depending on Previous Chemo- and Immunotherapy. Cancers, 12.","DOI":"10.3390\/cancers12051316"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2174\/1574893611666151119215823","article-title":"The Integrative Network of Gene Expression, MicroRNA, Methylation and Copy Number Variation in Colon and Rectal Cancer","volume":"11","author":"Huang","year":"2016","journal-title":"Curr. Bioinform."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3389\/fgene.2018.00422","article-title":"Identification of miR-200c and miR141-Mediated lncRNA-mRNA Crosstalks in Muscle-Invasive Bladder Cancer Subtypes","volume":"9","author":"Liu","year":"2018","journal-title":"Front. Genet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"8075","DOI":"10.1007\/s13277-015-4698-y","article-title":"Circulating miR-205: A promising biomarker for the detection and prognosis evaluation of bladder cancer","volume":"37","author":"Fang","year":"2015","journal-title":"Tumor Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.3892\/ijo.2012.1622","article-title":"Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer","volume":"41","author":"Yun","year":"2012","journal-title":"Int. J. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Borkowska, E.M., Konecki, T., Pietrusi\u0144ski, M., Borowiec, M., and Jab\u0142onowski, Z. (2019). MicroRNAs Which Can Prognosticate Aggressiveness of Bladder Cancer. Cancers, 11.","DOI":"10.3390\/cancers11101551"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.4111\/icu.2016.57.S1.S52","article-title":"Aberrantly expressed microRNAs in the context of bladder tumorigenesis","volume":"57","author":"Lee","year":"2016","journal-title":"Investig. Clin. Urol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.3892\/ol.2017.6621","article-title":"Expression levels of FGFR3 as a prognostic marker for the progression of primary pT1 bladder cancer and its association with mutation status","volume":"14","author":"Kang","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00428-014-1596-4","article-title":"FGFR3 mutations, but not FGFR3 expression and FGFR3 copy-number variations, are associated with favourable non-muscle invasive bladder cancer","volume":"465","author":"Neuzillet","year":"2014","journal-title":"Virchows Archiv"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1093\/nar\/gni178","article-title":"Real-time quantification of microRNAs by stem-loop RT-PCR","volume":"33","author":"Chen","year":"2005","journal-title":"Nucleic Acids Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00345-018-2503-4","article-title":"Molecular markers in bladder cancer","volume":"37","author":"Soria","year":"2019","journal-title":"World J. Urol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ucl.2015.08.005","article-title":"Current Status of Urinary Biomarkers for Detection and Surveillance of Bladder Cancer","volume":"43","author":"Mbeutcha","year":"2016","journal-title":"Urol. Clin. N. Am."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11934-018-0857-1","article-title":"Current Use and Promise of Urinary Markers for Urothelial Cancer","volume":"19","author":"Tabayoyong","year":"2018","journal-title":"Curr. Urol. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Blinova, E., Roshchin, D., Kogan, E.A., Samyshina, E., Demura, T., Deryabina, O., Suslova, I., Blinov, D., Zhdanov, P., and Osmanov, U. (2019). Patient-Derived Non-Muscular Invasive Bladder Cancer Xenografts of Main Molecular Subtypes of the Tumor for Anti-Pd-l1 Treatment Assessment. Cells, 8.","DOI":"10.3390\/cells8060526"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Pashaei, E., Guzel, E., Ozgurses, M.E., Demirel, G., Aydin, N., and Ozen, M. (2016). A Meta-Analysis: Identification of Common Mir-145 Target Genes that have Similar Behavior in Different GEO Datasets. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0161491"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Zhu, J., Li, Y., Luo, Y., Xu, J., Liufu, H., Tian, Z., Huang, C., Li, J., and Huang, C. (2019). A Feedback Loop Formed by ATG7\/Autophagy, FOXO3a\/miR-145 and PD-L1 Regulates Stem-Like Properties and Invasion in Human Bladder Cancer. Cancers, 11.","DOI":"10.3390\/cancers11030349"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur. Urol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.eururo.2017.04.015","article-title":"Prognostic Performance and Reproducibility of the 1973 and 2004\/2016 World Health Organization Grading Classification Systems in Non\u2013muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review","volume":"72","author":"Soukup","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1089\/bio.2016.0119","article-title":"Integrating Molecular Control to Improve Cryopreservation Outcome","volume":"15","author":"Baust","year":"2017","journal-title":"Biopreserv. Biobank."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Wang, C.C., Tsai, Y.C., and Jeng, Y.M. (2019). Biological significance of GATA3, cytokeratin 20, cytokeratin 5\/6 and p53 expression in muscle-invasive bladder cancer. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0221785"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3233\/BLC-150037","article-title":"Bladder Cancer Molecular Taxonomy: Summary from a Consensus Meeting","volume":"2","author":"Lerner","year":"2016","journal-title":"Bladder Cancer"},{"key":"ref_33","unstructured":"(2019, December 26). Ventana PD-L1 (SP263) Assay Staining in Urothelial Carcinoma. Interpretation Guide, Available online: https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf16\/p160046c.pdf."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/10\/11\/305\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:36:14Z","timestamp":1760178974000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/10\/11\/305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,23]]},"references-count":33,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["life10110305"],"URL":"https:\/\/doi.org\/10.3390\/life10110305","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,23]]}}}